Fairvalue-Calculator Fairvalue-Calculator
EN DE

Citius Oncology, Inc (CTOR) Fair Value & Analysis

Healthcare · US · Market cap $62.3M

Price$0.6850
Fair Value$0.3200
Upside-53.3%
Quality91/100
Evidence: Low Range $0.2400 – $0.4800

Fair value as of: Jun 25, 2026

Analysis

Citius Oncology, Inc (CTOR) currently trades at $0.6850, while our model-based Fair Value estimate is $0.3200 — implying the stock looks roughly 53.3% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Citius Oncology, Inc (CTOR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.3200 versus a price of $0.6850 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CTOR?
Our 21-model fair value for Citius Oncology, Inc is $0.3200 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.6850.
What is the quality score of CTOR?
Citius Oncology, Inc has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.